Atorvastatin / Dapagliflozin (Egis Pharmaceuticals)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAtorvastatin / Dapagliflozin (Egis Pharmaceuticals)
Drug Alias Nameatorvastatin+ dapagliflozin
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsSodium/glucose cotransporter 2 inhibitors
TargetsHMG-CoA reductaseSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Heart FailureRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEU
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEgis Pharmaceuticals PLC
China Registration ClassN/A

Develop Information

Active CompaniesEgis Pharmaceuticals PLC
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Heart FailureRenal Insufficiency, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A